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Abstract
Cutaneous sarcoidosis is a common presentation for pa-
tients with sarcoidosis. Rarely, patients can present with 
psoriasiform lesions mimicking chronic plaque psoriasis. 
Here, we present a case of psoriasiform sarcoidosis in a 
pregnant patient. Pregnancy represents a unique challenge 
to systemic treatments if topical management fails. Tumor 
necrosis factor alpha inhibitors warrant special consider-
ation during pregnancy.
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qday, and insulin. Physical examination revealed large, 
well-demarcated, hyperpigmented plaques with mica-
ceous scale on her upper extremities, knee, neck, and 
back (Figure 1). There were also thin hyperpigmented 
plaques on her temple, nose, cheeks, and chin. A punch 
biopsy of the arm showed granulomatous inflammation 
consisting of histiocytes and lymphocytes in discrete 
aggregations and abutting the hyperkeratotic and pso-
riasiform epidermis (Figure 2). Clinical pathologic corre-
lation was consistent with psoriasiform sarcoidosis.
The patient was started on topical corticosteroids 
and continued on hydroxychloroquine. The prednisone 
was to be tapered. At follow-up, there was moderate 
improvement of skin lesions with near complete reso-
lution of scaling, but still with significant classic sarcoi-
dal appearance. Due to active pulmonary lesions, her 
CAse RepoRt
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Introduction
Sarcoidosis is a systemic inflammatory disease cha-
racterized by granuloma formation in multiple organs 
of the body, with a predilection for the lungs, skin, and 
eyes. Cutaneous sarcoidosis presents in myriad forms, 
appearing in about 25% of patients, while psoriasiform 
lesions are a rare manifestation in only about 0.9% [1]. 
We report the case of a 40-year-old woman at 10-we-
eks’ gestation with psoriasiform sarcoidosis.
Case Report
A 40-year-old African-American woman at 10-we-
eks gestation with a history including active pulmonary 
sarcoidosis and diabetes was referred for several-year 
history of skin lesions by maternal-fetal medicine, whi-
ch recently became scalier. Her medications included 
hydroxychloroquine 200 mg qday, prednisone 20 mg 
         
Figure 1: Well-demarcated, hyperpigmented plaques with 
micaceous scale on upper extremities.
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sional corticosteroids, whose benefits can often be seen 
in a matter of weeks [9]. While methotrexate and an-
ti-malarials are also widely used, evidence for their effi-
cacy is limited [10]. Recently, the spotlight has focused 
on TNF-α inhibitors, such as infliximab and adalimumab. 
The pivotal role of TNF-α in mediating the formation 
and maintenance of sarcoidal granulomas makes it an 
exciting therapeutic target [11]. Numerous studies have 
shown extremely promising benefits for patients recal-
citrant to first and second line treatments [12-15].
Our patient presented at 10-weeks gestation with 
psoriasiform sarcoidosis, and she showed an incomple-
te response from topical steroids and hydroxychloro-
quine. The ensuing discussion with a multi-disciplinary 
team should revolve around increasing the dose of hy-
droxychloroquine versus considering a TNF-α inhibitor. 
However, pregnancy requires special consideration due 
to additional concerns regarding the risks to the fetus. 
Studies comparing TNF-α inhibitors to placebo in pre-
gnant patients with irritable bowel disease and rheuma-
toid arthritis have not consistently shown strong asso-
ciations with rates of preterm birth, spontaneous mi-
scarriage, and congenital anomalies [16-19]. However, 
it has generally been recommended that TNF-α inhibi-
tors be stopped in the second or third trimester when 
placental transfer is greatest. Certolizumab, a fragment 
of a monoclonal antibody specific to TNF-α, may not 
need to be stopped, since it does not as readily cross the 
placenta [19-21]. The decision to start TNF-α inhibitors 
in recalcitrant cases should be made on a case-by-case 
basis with multi-disciplinary input.
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treatment was to be discussed with pulmonology and 
maternal-fetal medicine regarding the decision to incre-
ase hydroxychloroquine or start a tumor necrosis factor 
alpha (TNF-α) inhibitor.
Discussion
While the etiology of sarcoidosis has yet to be ful-
ly elucidated, environmental exposures and infectious 
agents have been suspected [2]. The presence of 
non-caseating granulomas is firmly established as the 
key pathologic finding. These characteristic sarcoidal 
granulomas consist predominantly of macrophages 
and epithelioid cells with peripherally surrounding lym-
phocytes. The pathological process begins when an unk-
nown sarcoidal antigen is phagocytosed by antigen-pre-
senting cells. This subsequently stimulates CD4+ T cells 
into secreting Th1-associated cytokines, such as IL-12, 
IL-15, IL-18, interferon gamma, and TNF-α, leading to 
the formation of the characteristic sarcoidal granulo-
mas [3]. Many of these cytokines are also elevated in 
psoriasis, producing irregular hyperproliferation and 
differentiation of keratinocytes with histopathology de-
monstrating parakeratosis, intraepidermal neutrophilic 
infiltrations, and hypogranulosis [4].
Investigations into the overlap between sarcoidosis 
and psoriasis have focused heavily on the similar pa-
thologic roles of Th1 cells. Both disorders have been 
associated with specific gene polymorphisms, such as 
IL23R, and psoriasis itself has been linked with 14 other 
autoimmune conditions, further strengthening the ar-
gument for shared pathways [5,6]. Paradoxically, sarcoi-
dosis and psoriasis have both been reported after the 
initiation of TNF-α inhibitors, hinting again at homolo-
gous pathologic factors [7]. A previous report theorized 
that overexpression of TNF-α from both diseases may 
be responsible for the psoriasiform lesions arising in 
areas of cutaneous sarcoidosis [8].
For now, the goal of treating sarcoidosis focuses on 
suppressing symptoms, as the underlying cause remains 
elusive. First line therapy consists of topical and intrale-
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Figure 2: Granulomatous inflammation consisting of histiocytes and lymphocytes in discrete aggregations and abutting the 
hyperkeratotic and psoriasiform epidermis. (A) H&E, original magnification x4; (B) H&E, original magnification x20.
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